No trading action warranted. Monitor for future pipeline catalysts or clinical data readouts, which are the primary value drivers for this pre-revenue biotech.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 24 $36.28entry
- T+1 · 5mo ago +0.03%α −0.12% · $36.29
- T+5 · 5mo ago −0.30%α −2.01% · $36.17
- T+20 · 4mo ago −3.53%α −5.46% · $35.00
- T+60 · 2mo ago +6.42%α +3.58% · $38.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IDEAYA Biosciences filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders, where all three proposals passed: election of three Class I directors, ratification of PricewaterhouseCoopers as auditor, and advisory approval of executive compensation. Separately, the Board elected CEO Yujiro S. Hata as Chairman and Terry Rosen as Lead Independent Director. This is a routine governance filing with no material financial or operational impact.
Key Facts
- Annual Meeting held June 16, 2026; all three proposals passed.
- Directors elected: Yujiro S. Hata (70.5M for), M. Garret Hampton (56.7M for), Catherine J. Mackey (70.3M for).
- Ratification of PwC as auditor: 82.6M for, 141K against.
- Advisory vote on executive compensation: 64.3M for, 8.3M against.
- Board elected Yujiro S. Hata as Chairman and Terry Rosen as Lead Independent Director, effective June 16, 2026.
- 87,860,920 shares outstanding and entitled to vote as of record date April 20, 2026.
Financial Impact
No financial impact; routine governance and board leadership changes.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-279427 |
| Document: 0001193125-26-279427-index-headers.html | 0001193125-26-279427 |
| Document: 0001193125-26-279427-index.html | 0001193125-26-279427 |
| Document: 0001193125-26-279427.txt | 0001193125-26-279427 |
Track record
13 reports on IDYA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Viewing Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers